MANKIND logo

Mankind Pharma Limited Stock Price

NSEI:MANKIND Community·₹978.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

MANKIND Share Price Performance

₹2,309.10
-439.75 (-16.00%)
7.4% overvalued intrinsic discount
₹2,150.00
Fair Value
₹2,309.10
-439.75 (-16.00%)
7.4% overvalued intrinsic discount
₹2,150.00
Fair Value
Price ₹2,309.10
AnalystLowTarget ₹2,150.00
AnalystConsensusTarget ₹2,799.65
AnalystHighTarget ₹3,300.00

MANKIND Community Narratives

AnalystLowTarget·
Fair Value ₹2.15k 7.4% overvalued intrinsic discount

Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹2.8k 17.5% undervalued intrinsic discount

Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AnalystHighTarget·
Fair Value ₹3.3k 30.0% undervalued intrinsic discount

India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
₹2.15k
7.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
13.26% p.a.
Profit Margin
16.78%
Future PE
44.13x
Share price in 2028
₹3.08k

Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.

1 Risk
2 Rewards

Mankind Pharma Limited Key Details

₹129.1b

Revenue

₹39.0b

Cost of Revenue

₹90.1b

Gross Profit

₹71.1b

Other Expenses

₹18.9b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
45.86
69.76%
14.66%
58.4%
View Full Analysis

About MANKIND

Founded
1991
Employees
26978
CEO
Sheetal Arora
WebsiteView website
www.mankindpharma.com

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Recent MANKIND News & Updates

Recent updates

No updates